Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data on rezafungin clinical safety and pharmacokinetics in people with hepatic impairment, at IDWeek taking place virtually from September 29-October 3, 2021.

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 166.67% and 415.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its corporate activities and product pipeline.

Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021.

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

Cidara is in clinical trials with a fungus therapy and has an antiviral platform.

Cidara Therapeutics: Rezafungin Data Could Bring Value

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.

Cidara Therapeutics Provides Leadership Update

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021.

Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021.

Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidara's novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2021 Conference, which takes place online from June 11-12, 2021.

Cidara to Present at Mycology 2021 Conference

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2021 and provided an update on its corporate activities and product pipeline.

Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.

Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Johnson & Johnson

Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.

Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies

ACADIA Pharma

Bio-Path Holdings

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejection: Acadia said the FDA has issued a complete response letter regarding its supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis.

Why Acadia Pharma, Bio-path And Cidara Are Moving Today

Cidara Therapeutics Inc (NASDAQ: CDTX) has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize Cidara's Cloudbreak antiviral conjugates (AVCs) for seasonal and pandemic influenza.  Under the collaboration, Cidara will be responsible for developing and manufacturing the first influenza AVC, CD388, into the clinic and through Phase 2 development.

Cidara Therapeutics Stock Rises After Collaboration Agreement Janssen For Influenza Candidates

The stock price of Cidara Therapeutics, Inc. (Nasdaq: CDTX) increased by over 5% pre-market. This is why it happened.

Cidara Therapeutics Stock Price Increased Over 5% Pre-Market: Why It Happened

Collaboration includes exclusive worldwide rights to Cidara's CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding

Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months and full year ended December 31, 2020 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programs Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programs

Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7th European Scientific Working Group on Influenza (ESWI) Influenza Conference, which takes place virtually Dec. 6-9, 2020.

Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020.

Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCONx Conference.

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q3 Loss, Misses Revenue Estimates

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.

News for Cidara Therapeutics Stock (CDTX)